Impact of alectinib on survival after crizotinib failure in ALK-positive NSCLC patients

Authors :: Yoshitsugu Horio
Kosuke Tanaka
Junichi Shimizu
Yuko Oya
Yasushi Yatabe
Tatsuya Yoshida
Toyoaki Hida
Source :: Journal of Clinical Oncology. 33:e19138-e19138
Publication Year :: 2015
Publisher :: American Society of Clinical Oncology (ASCO), 2015.
Abstract: e19138 Background: The next generation ALK inhibitor, alectinib, reportedly has potent efficacy after crizotinib failure in ALK-positive NSCLC patients. In the present study, we investigated progre...

Subjects :: Alectinib
Oncology
Cancer Research
medicine.medical_specialty
Pathology
Crizotinib
medicine.drug_class
business.industry
ALK-Positive
ALK inhibitor
hemic and lymphatic diseases
Internal medicine
medicine
business
medicine.drug

Tools